CSIMarket
 


Acceleron Pharma inc  (XLRN)
Other Ticker:  
 
 

XLRN's Net Income Growth by Quarter and Year

Acceleron Pharma Inc's Net Income results by quarter and year




XLRN Net Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - -57.40 -23.57 -34.74
III Quarter September -70.47 -39.25 -45.37 -28.98
II Quarter June -63.52 -18.45 -17.86 -28.94
I Quarter March -63.47 -50.94 -38.05 -26.22
FY   -197.46 -166.04 -124.85 -118.88



XLRN Net Income third quarter 2021 Y/Y Growth Comment
Acceleron Pharma inc in the third quarter 2021 recorded net loss of $ -70.47 millions.

According to the results reported in the third quarter 2021, Acceleron Pharma Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Acceleron Pharma Inc' s Net Income no change of % ranks overall at the positon no. in the third quarter 2021.




XLRN Net Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Acceleron Pharma Inc's third quarter 2021 Net Income $ -70.47 millions XLRN's Income Statement
Acceleron Pharma Inc's third quarter 2020 Net Income $ -39.25 millions Quarterly XLRN's Income Statement
New: More XLRN's historic Net Income Growth >>


XLRN Net Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Acceleron Pharma Inc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XLRN's III. Quarter Q/Q Net Income Comment
Current results of -70.47 millions by Acceleron Pharma inc come out even worse compare to the -63.52 millions net loss in the second quarter.

Within Biotechnology & Pharmaceuticals industry Acceleron Pharma inc achieved highest sequential Net Income growth. While Acceleron Pharma Inc's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XLRN's III. Quarter Q/Q Net Income Comment
Recent results of -70.47 millions by Acceleron Pharma inc come out even less good if you take a look at -63.52 millions net loss in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Acceleron Pharma inc achieved highest sequential Net Income growth. While Acceleron Pharma Inc's Net Income growth quarter on quarter, overall rank is .


Acceleron Pharma Inc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Net Income 12 Months Ending $ -254.85 $ -223.63 $ -178.56 $ -166.03 $ -132.21
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Acceleron Pharma Inc' has realized cumulative trailing twelve months net loss of $ -255 millions in the Sep 30 2021 period.
The results are detiriorating as the cumulative net loss is inflating from $ -223.63 millions in TTM ending quarter Jun 30 2021 and $ -138.333 millions for the twelve months ending in the quarter Sep 30 2020 Eric Walker mentioned.

Acceleron Pharma inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Acceleron Pharma Inc' has realized cumulative trailing twelve months net loss of $ -255 millions in the Sep 30 2021 period.
The results are worsening as the cumulative net loss is getting bigger from $ -223.63 millions for the period from Jun 30 2021 to Sep 30 2020 and $ -138.333 millions for the twelve months ending in the quarter a year ago Eric Walker mentioned.

Acceleron Pharma inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
XLRN's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for XLRN's Competitors
Net Income Growth for Acceleron Pharma Inc's Suppliers
Net Income Growth for XLRN's Customers

You may also want to know
XLRN's Annual Growth Rates XLRN's Profitability Ratios XLRN's Asset Turnover Ratio XLRN's Dividend Growth
XLRN's Roe XLRN's Valuation Ratios XLRN's Financial Strength Ratios XLRN's Dividend Payout Ratio
XLRN's Roa XLRN's Inventory Turnover Ratio XLRN's Growth Rates XLRN's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2021
Lhc Group Inc 133.65%$ 133.646 millions
Repligen Corp130.20%$ 130.195 millions
Conmed Corporation118.22%$ 118.219 millions
West Pharmaceutical Services Inc 113.37%$ 113.366 millions
Becton Dickinson And Company107.09%$ 107.087 millions
Radnet Inc 106.79%$ 106.787 millions
Bio techne Corp106.56%$ 106.561 millions
Regeneron Pharmaceuticals Inc 93.82%$ 93.825 millions
Acadia Healthcare Company Inc 80.77%$ 80.773 millions
Tenax Therapeutics Inc 71.08%$ 71.077 millions
Teleflex Incorporated70.84%$ 70.843 millions
Abbott Laboratories70.45%$ 70.455 millions
Ironwood Pharmaceuticals inc 62.23%$ 62.232 millions
Fonar Corporation59.40%$ 59.397 millions
Bruker Corporation59.31%$ 59.313 millions
Merck and Co Inc 55.21%$ 55.212 millions
Dentsply Sirona Inc 54.98%$ 54.982 millions
Fibrogen Inc 50.88%$ 50.885 millions
Davita Inc 46.99%$ 46.986 millions
Utah Medical Products Inc43.40%$ 43.403 millions
Corcept Therapeutics Inc40.91%$ 40.906 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com